Biotech billionaire Patrick Soon-Shiong’s ImmunityBio Inc. has seen its shares triple in just three weeks. This explosive rally triggered a short squeeze, forcing bears who bet against the stock to close their positions at a significant loss. The move caught many off guard in a volatile sector.

The surge follows recent clinical updates for ImmunityBio’s cancer immunotherapy pipeline, a key area of investor focus. For the biotech industry, such rapid gains highlight the high-stakes nature of drug development and the potent impact of positive trial data on market valuations and trader positioning.

Short sellers now face steep losses, while long-term investors watch for the stock’s next move. Market participants will scrutinize upcoming trial milestones and regulatory decisions. The episode underscores the fragile balance between clinical promise and commercial reality in speculative biotech investing.